key: cord-0791610-oq6ldke3
authors: Levinson, Stanley S
title: SARS-CoV-2 Serology - Need for Quantitative Testing and Interpretive Reporting
date: 2020-08-11
journal: J Appl Lab Med
DOI: 10.1093/jalm/jfaa147
sha: 1b68f72d6fd4a70642f1836e6774d5a2a265af3c
doc_id: 791610
cord_uid: oq6ldke3

nan

There is a concern about false negative results (FNR) and an urgent need for quantitative testing to avoid FNR and for better clarifying FPR. Persons with mild infection may have much lower concentrations of specific nucleocapsid antibody than those with severe infection (2) . Many reference ranges for qualitative assays were developed from hospitalized patients with severe disease.

Many widely used qualitative assays, such as those from Roche Diagnostics and Abbott seem to have optimized cutoffs to show 100% diagnostic sensitivity with hospitalized patients, while still keeping the cutoff high enough to obtain >99% specificity (1). This high degree of specificity suggests that the cutoffs are too high.

Recent publications support this contention. The diagnostic sensitivity for the Roche assay using the manufacturer's prescribed cutoff was 91.7 % but using a receiver operator characteristic curve cutoff the sensitivity was 100% (3). ELISA for spike and nucleocapsid antibodies both showed about 80 sensitivity (4) . These studies used sera from hospitalized patients.

Until a vaccine is available, the prevalence will increase which will reduce the FPR. But as the prevalence increases, the number of false negatives will increase. This produces a quandary for medical providers since many Institutions are now screening unknown patients. One way to reduce uncertainty is to provide quantitative testing.

For example, at some high cutoff, one can say likely immune. At a lower concentration, one can say this person may be immune based on clinical history.

Although we have no exact idea of likelihood, based on history and antibody concentration, one can make a credible guess.

IgA is important for protecting the intestinal mucosa but also protects the lung mucosal surfaces. It has been reported increased in SARS-CoV-2 infection, but it is of little value in interpreting SARS-CoV-2 serology where IgM rises early, indicating recent infection, and IgG later. In the past, concentration was reported as a titer with serial dilutions. Thus, a high titer of IgG on a young person that never had apparent disease, but was in the presence of a known confirmed contact, implies a higher probability of true positive and likely infection. IgM with rising or falling titer would confirm recent infection. In fact, quantitative IgM assays can be useful for contact tracing in subclinical and mild cases since analytically sensitive methods can detect IgM as early as 5.5 days after symptom onset and detected more positive cases than an RNA assay (5).

Because of better purification and detection techniques, titration is no longer necessary. Newer sensitive methods can detect different concentrations over a wide range. For example, the Manufacturer's positive cutoff for the Diasorn method for IgG against spike protein is >15 AU/mL(1), the limit of detection is about 5AU/mL and the maximum detection limit is 80 AU/mL. Cutoffs can be set over this wide spectrum.

Abbott and Roche assays, are directed against nucleocapsid protein while others, such as Diasorin are directed against spike protein. Some vaccines are directed against specific spike protein (6) so that the nucleocapsid serology tests will not show a reaction. The FDA has suggested confirming positives with a second assay. It seems it would be best to use an assay with a different antigen. Certainly quantitative measurement of both spike and nuceocapsid protein antibodies will help define these issues In local discussions, one hospital performing screening found a 0.01% incidence of SARS-CoV-2 serology positivity which caused concern that the qualitative test being used was missing true positives. A 0.07% prevalence seems more reasonable. If the prevalence was truly 0.07% but the measured incidence only 0.01%, there would be 7 false negative to every 1 true positive result. On the other hand assuming a diagnostic specificity of 99.6%, if the prevalence was really 0.1 %, there would be 4 false positive to every one true positive result -PPV = a dismal 20%.

Although manufacturers of qualitative test kits suggest reporting results as positive or negative, reactive or nonreactive, it seems laboratories should give more information on a report. An interpretive statement: "as to how FPR will depend on the prevalence in the community, which will differ in different communities, with a simple example and a statement regarding FNR, such as this cutoff was derived from hospitalized patients with more severe infections, those with less intense infection may test negative." Although we have a long way to go, clearly, quantitative assays for all 5 specific proteins and IgG and IgM classes are needed. Many of the current kits can be modified to provide this information. This, along with clinical history, will help in clarification. Moreover, it is important that clinical laboratory professionals be aware of these concepts for educated consulting with Medical staff and for interpretive reporting. 

Viral kinetics and antibody responses in patients with COVID-19

Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques